Brian Murphy, MD, MPH, MBA, MS
Chief Executive Officer, Chief Medical Officer and Director
Dr. Murphy has more than 20 years of experience in drug development and evaluation. Most recently he served as the Chief Medical Officer of Eiger Biopharmaceuticals (NASDAQ: EIGR), and prior to that held the same position at Bausch Health Companies (NYSE: BHC; formerly Valeant Pharmaceuticals International). Dr. Murphy has also served as Vice President of Sales and Marketing-Hepatology at InterMune, Inc., and Medical Director of North America (Anti-Infectives and Transplant) at Hoffmann-LaRoche, as well as Assistant Professor of Medicine at New York Medical College and Director of the Clinical Strategies Programs at St. Vincent's Hospital in New York City. He is board-certified in internal medicine, and earned his MD, MPH (general public health), and MS (pharmacology) degrees from New York Medical College and is a graduate of the Harvard School of Public Health (MPH in Health Policy and Management). He earned his MBA at the Columbia University Graduate School of Business. Dr. Murphy also completed parallel fellowships in clinical epidemiology/infectious diseases and medical ethics at Harvard affiliates, Massachusetts General Hospital and Brigham and Women’s Hospital, respectively.
Doug Cesario, MBA
Chief Financial Officer
Mr. Cesario has more than 15 years of financial and operational experience, most recently as Chief Financial Officer of Kaiser Permanente Foundation Hospitals and Health Plan in the Orange County, California marketplace, where he managed the financial performance of the health system with an operating budget of over $1 billion per year. Prior financial leadership positions have included founder of Community Capital Advisory Group, a real estate advisory and investment company; director of Skye Automotive; a private equity fund; and corporate finance associate at both full service and boutique investment banking firms. Mr. Cesario earned his MBA at the UCLA Anderson School of Management.
Dennis Kim, MD, MBA
Chief Medical Officer
Dr. Kim is a physician and biotechnology executive with over 20 years of experience in drug and product development as well as corporate strategy in biotech and medical technology. Prior to joining Emerald, Dr. Kim was Chief Medical Officer at Zafgen, Senior Vice President of Medical and Clinical Affairs at Orexigen Therapeutics, Chief Medical Officer at EnteroMedics, and Executive Director of Corporate Strategy at Amylin Pharmaceuticals. He holds an MD from the University of Health Sciences, The Chicago Medical School, an MBA from UCSD Rady School of Management, and a BS in Biology from the University of California. In addition to being board-certified in internal medicine, Dr. Kim completed the Endocrinology and Metabolism Specialty Fellowship Training Program at the UCSD School of Medicine.
Executive Director, Clinical Operations
Ms. Chen has 20 years of global clinical research experience working with early and late-stage biotech companies, particularly in the planning and execution of clinical trials for a variety of indications, including oncology, hepatology, autoimmune, and orphan diseases. Prior to joining Emerald, Ms. Chen served as the Head of Clinical Operations at Zafgen, Inc., where she was involved in study design, managing study conduct, and overseeing clinical trial budgets and timelines across multiple clinical programs. Additionally, Ms. Chen held various positions in clinical operations at Salmedix and Ionis, and consulting positions at Cephalon, Altair Therapeutics, Auspex Pharmaceuticals, MedGene, Inc., Cabrellis Pharmaceuticals, and Santaris Pharma.Ms. Chen is a graduate of the University of California, San Diego.